Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Prostate-specific membrane antigen positron emission tomography/computed tomography combined with sentinel node biopsy for primary lymph node staging in prostate cancer.

Hinsenveld FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, Donswijk ML, Tillier CN, Vegt E, van Muilekom HAM, van Oosterom MN, van Leeuwen FWB, van der Poel HG.

J Nucl Med. 2019 Sep 27. pii: jnumed.119.232199. doi: 10.2967/jnumed.119.232199. [Epub ahead of print]

PMID:
31562222
2.

Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.

Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H.

J Transl Med. 2017 Nov 7;15(1):230. doi: 10.1186/s12967-017-1333-2.

3.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
4.
5.

68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP.

Eur Urol. 2016 Oct;70(4):553-557. doi: 10.1016/j.eururo.2015.12.051. Epub 2016 Jan 19.

PMID:
26810345
6.

Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.

van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.

BJU Int. 2017 Feb;119(2):209-215. doi: 10.1111/bju.13540. Epub 2016 Jun 18.

7.

Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.

Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, Musi G, Butticè S, Salonia A, Briganti A, Damiano R.

Urology. 2017 Aug;106:139-145. doi: 10.1016/j.urology.2017.04.019. Epub 2017 Apr 21.

PMID:
28438628
8.

Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C.

Eur Urol. 2016 Mar;69(3):393-6. doi: 10.1016/j.eururo.2015.06.010. Epub 2015 Jun 25.

PMID:
26116958
9.

Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.

van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.

BJU Int. 2019 Jul;124(1):62-68. doi: 10.1111/bju.14506. Epub 2019 Apr 7.

PMID:
30074667
10.

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.

Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, Wetterauer U, Schultze-Seemann W, Meyer PT.

Theranostics. 2017 Apr 10;7(6):1770-1780. doi: 10.7150/thno.18421. eCollection 2017.

12.

68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.

Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.

13.

Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.

Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO.

Prostate. 2015 Dec;75(16):1934-40. doi: 10.1002/pros.23091. Epub 2015 Sep 10.

PMID:
26356236
14.

Multispectral Fluorescence Imaging During Robot-assisted Laparoscopic Sentinel Node Biopsy: A First Step Towards a Fluorescence-based Anatomic Roadmap.

van den Berg NS, Buckle T, KleinJan GH, van der Poel HG, van Leeuwen FWB.

Eur Urol. 2017 Jul;72(1):110-117. doi: 10.1016/j.eururo.2016.06.012. Epub 2016 Jun 23.

PMID:
27345689
15.

Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M.

J Urol. 2016 May;195(5):1436-1443. doi: 10.1016/j.juro.2015.12.025. Epub 2015 Dec 9.

PMID:
26682756
16.

Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.

Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L, Wong D.

J Urol. 2019 Apr;201(4):815-820. doi: 10.1097/JU.0000000000000053.

PMID:
30672842
17.

68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.

J Nucl Med. 2017 Dec;58(12):1949-1955. doi: 10.2967/jnumed.116.185033. Epub 2017 Jun 21.

18.

68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer.

Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Rupp NJ, Huellner M, Messerli M, Rüschoff JH, Ter Voert EEGW, Hermanns T, Burger IA.

Eur J Nucl Med Mol Imaging. 2019 Sep 14. doi: 10.1007/s00259-019-04511-4. [Epub ahead of print]

PMID:
31522272
19.

Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.

Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.

BJU Int. 2019 Sep;124(3):401-407. doi: 10.1111/bju.14828. Epub 2019 Jul 2.

PMID:
31141284
20.

Multimodal hybrid imaging agents for sentinel node mapping as a means to (re)connect nuclear medicine to advances made in robot-assisted surgery.

KleinJan GH, van den Berg NS, de Jong J, Wit EM, Thygessen H, Vegt E, van der Poel HG, van Leeuwen FW.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1278-87. doi: 10.1007/s00259-015-3292-2. Epub 2016 Jan 15.

Supplemental Content

Support Center